# Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

> **NCT02117479** · PHASE3 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 321 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Placebo
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02117479
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2016-02
- **Final completion:** 2016-12
- **Target enrollment:** 321 (ACTUAL)
- **Why stopped:** The study was terminated early based on the results of the planned interim analysis.
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117479, "Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02117479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*